Literature DB >> 30467886

Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.

Gregory Sinner1, Hesham R Omar2, You W Lin1, Samy C Elayi1, Maya E Guglin1.   

Abstract

INTRODUCTION: Current guidelines recommend at least 3 months of guideline-directed medical therapy (GDMT) for patients with a new onset of non-ischemic cardiomyopathy (NICM) and left bundle branch block (LBBB) prior to cardiac resynchronization therapy (CRT). For patients who do not receive optimal GDMT, response to CRT is unknown.
METHODS: Patients with NICM and LBBB with QRS ≥ 120 ms were identified among all patients who underwent CRT. Patients who received GDMT for ≥ 3 months before CRT were compared to those who did not. Among 38 patients who met inclusion criteria, 24 received optimal GDMT prior to implantation (Group 1) and 14 did not (Group 2).
RESULTS: QRS narrowing occurred in Group 1 (160 ± 9 ms to 138 ± 20 ms, P = 0.001) and Group 2 (160 ± 17 ms to 139 ± 30 ms, P = 0.021). Left ventricular ejection fraction (LVEF) improvement occurred in Group 1 (21.3 ± 5.9% to 34.4 ± 13.9%, P < 0.001) and Group 2 (18.8 ± 4.7% to 31.1 ± 13%, P = 0.010). QRS interval and LVEF changes were similar between groups (P = NS). There was a trend towards greater CRT response in women than in men, although differences did not reach statistical significance.
CONCLUSION: In patients with NICM and LBBB, CRT is associated with improvements in LV size and function independent of prior GDMT. The ability of resynchronization to improve LVEF without GDMT suggests that CRT without waiting 3 months for GDMT optimization may benefit some patients with NICM and LBBB.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; guideline-directed medical therapy; left bundle branch block; non-ischemic cardiomyopathy

Mesh:

Substances:

Year:  2018        PMID: 30467886      PMCID: PMC6436512          DOI: 10.1002/clc.23123

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  43 in total

1.  Cardiac-resynchronization therapy for mild-to-moderate heart failure.

Authors:  Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.

Authors:  William T Abraham; James B Young; Angel R León; Stuart Adler; Alan J Bank; Shelley A Hall; Randy Lieberman; L Bing Liem; John B O'Connell; John S Schroeder; Kevin R Wheelan
Journal:  Circulation       Date:  2004-10-25       Impact factor: 29.690

3.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  J Am Coll Cardiol       Date:  2013-06-05       Impact factor: 24.094

4.  Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.

Authors:  Abdul Ghani; Peter Paul H M Delnoy; Ahmet Adiyaman; Jan Paul Ottervanger; Anand R Ramdat Misier; Jaap Jan J Smit; Arif Elvan
Journal:  Clin Cardiol       Date:  2017-03-14       Impact factor: 2.882

5.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Cynthia M Tracy; Andrew E Epstein; Dawood Darbar; John P DiMarco; Sandra B Dunbar; N A Mark Estes; T Bruce Ferguson; Stephen C Hammill; Pamela E Karasik; Mark S Link; Joseph E Marine; Mark H Schoenfeld; Amit J Shanker; Michael J Silka; Lynne Warner Stevenson; William G Stevenson; Paul D Varosy
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

6.  Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.

Authors:  Gregory Sinner; Hesham R Omar; You W Lin; Samy C Elayi; Maya E Guglin
Journal:  Clin Cardiol       Date:  2018-12-15       Impact factor: 2.882

7.  Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.

Authors:  Jonathan C Hsu; Scott D Solomon; Mikhail Bourgoun; Scott McNitt; Ilan Goldenberg; Helmut Klein; Arthur J Moss; Elyse Foster
Journal:  J Am Coll Cardiol       Date:  2012-06-19       Impact factor: 24.094

8.  Cardiac resynchronization therapy in left ventricular hypertrabeculation/non-compaction and myopathy.

Authors:  Claudia Stöllberger; Gerhard Blazek; Elisabeth Bucher; Josef Finsterer
Journal:  Europace       Date:  2007-11-19       Impact factor: 5.214

9.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

10.  Identification of 'super-responders' to cardiac resynchronization therapy: the importance of symptom duration and left ventricular geometry.

Authors:  Natália António; Rogério Teixeira; Lourenço Coelho; Carolina Lourenço; Pedro Monteiro; Miguel Ventura; João Cristóvão; Luís Elvas; Lino Gonçalves; Luís A Providência
Journal:  Europace       Date:  2009-03       Impact factor: 5.214

View more
  1 in total

1.  Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.

Authors:  Gregory Sinner; Hesham R Omar; You W Lin; Samy C Elayi; Maya E Guglin
Journal:  Clin Cardiol       Date:  2018-12-15       Impact factor: 2.882

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.